Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
Weathering the storm: Another biotech braves Covid-19 in upsized IPO
6 years ago
Startups
Coronavirus
Merck-partnered antibody maker readies $300M IPO as HKEX picks up pace
6 years ago
China
Another protein degradation biotech emerges, with the promise of a new approach from an old hand
6 years ago
Startups
Another day, another boatload for biotech. Deerfield adds $840M to rush of venture dollars
6 years ago
Lilly Asia Ventures co-leads $100M+ round for Chinese biotech and its late-stage lupus drug
6 years ago
China
Ahead of US IPO, Legend Biotech adds $150M, top-tier investors to back CAR-T pipeline
6 years ago
R&D
A small, obscure biotech just won big with their IPO. In this market. Are you kidding me?
6 years ago
Bioregnum
Opinion
Investing in the time of coronavirus: the good, the bad and the hopeful, as biotech VC firms close funds worth $3B
6 years ago
In Focus
Dynacure secures $55M as their Ionis-developed drug moves into clinic
6 years ago
Cell/Gene Tx
Stepping out alongside ARCH's record raise, Flagship adds a $1.1B monster fund of its own
6 years ago
ARCH chief Bob Nelsen has $1.5B to prove 2 simple points: ‘We’re in the most innovative time ever’ and investors are staying
6 years ago
‘There was a growing weariness’: Rushing against a pandemic clock, Aspen Neuroscience secures $70M Series A
6 years ago
ITeos nabs $125M as they prep Keytruda combination trial — if Covid-19 will let them
6 years ago
R&D
A quiver of arrows for immune disorders: Pandion scores $80M in fresh funding
6 years ago
Startups
Can a pair of top AveXis alumni steer a new gene therapy upstart to R&D glory? 3 VCs bet $60M on it
6 years ago
R&D
Undeterred by a pandemic, Gilde Healthcare raises their largest fund yet
6 years ago
Unfazed by disruptions, Cowen's investment arm backs AM-Pharma's $176M pivotal plan around lethal condition
6 years ago
David Hallal bags another whopper round, looking to recruit more cell and gene therapy upstarts to ElevateBio BaseCamp
6 years ago
Startups
R&D
A Singapore VC raises $200M for a new round, but will Covid-19 prevent it from raising the rest?
6 years ago
Coronavirus
Coupling mRNA with tRNA and new delivery tech, MPM and OrbiMed help birth new $80M biotech into a slowed down world
6 years ago
Startups
SutroVax lands another $100M+ in upstart quest against Pfizer’s blockbuster Prevnar 13
6 years ago
Kallyope lands $112 million Series C to ride the gut-brain axis for another 3 years
6 years ago
A key player behind 2 multibillion-dollar biotech M&A deals is back in the startup business
6 years ago
Startups
InnoCare IPO oversubscribed 300x as Hong Kong investors turned to biotech amid runoff
6 years ago
China
First page
Previous page
101
102
103
104
105
106
107
Next page
Last page